- Home
- TENX vs MRKR Comparison
TENX vs MRKR Comparison
Compare TENX & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- MRKR
- Stock Information
- Founded
- TENX 1967
- MRKR N/A
- Country
- TENX United States
- MRKR United States
- Employees
- TENX N/A
- MRKR N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- MRKR Health Care
- Exchange
- TENX Nasdaq
- MRKR Nasdaq
- Market Cap
- TENX 21.6M
- MRKR 19.1M
- IPO Year
- TENX N/A
- MRKR N/A
- Fundamental
- Price
- TENX $6.17
- MRKR $1.47
- Analyst Decision
- TENX Strong Buy
- MRKR Strong Buy
- Analyst Count
- TENX 3
- MRKR 3
- Target Price
- TENX $16.00
- MRKR $13.17
- AVG Volume (30 Days)
- TENX 35.4K
- MRKR 231.4K
- Earning Date
- TENX 08-12-2025
- MRKR 08-13-2025
- Dividend Yield
- TENX N/A
- MRKR N/A
- EPS Growth
- TENX N/A
- MRKR N/A
- EPS
- TENX N/A
- MRKR N/A
- Revenue
- TENX N/A
- MRKR $5,696,123.00
- Revenue This Year
- TENX N/A
- MRKR N/A
- Revenue Next Year
- TENX N/A
- MRKR $11.28
- P/E Ratio
- TENX N/A
- MRKR N/A
- Revenue Growth
- TENX N/A
- MRKR 71.53
- 52 Week Low
- TENX $2.80
- MRKR $0.95
- 52 Week High
- TENX $7.89
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- TENX 51.83
- MRKR 50.81
- Support Level
- TENX $5.62
- MRKR $1.41
- Resistance Level
- TENX $6.35
- MRKR $1.53
- Average True Range (ATR)
- TENX 0.46
- MRKR 0.16
- MACD
- TENX 0.01
- MRKR -0.03
- Stochastic Oscillator
- TENX 41.49
- MRKR 9.43
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.